Humanized and chimeric monoclonal antibodies to cd47
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsJie Liu, Irving L. Weissman, Ravindra Majeti
Life of this patent
Estimating the term…
Abstract
Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
Claims17
1-28. (canceled)
An isolated chimeric or humanized antibody that specifically binds to human CD47, and comprises at least one CDR sequence as set forth in SEQ ID NO:28-33.
A method of modulating phagocytosis, the method comprising the step of administering to a subject a therapeutically effective amount of an antibody set forth in claim 1, in a dose effective to modulate phagocytosis.
Dependencies are inferred from the claim text.